Role of fibrinolytic therapy in the current era of ST-segment elevation myocardial infarction management

American Heart Journal

Volumn 151, Issue 6 SUPPL., 2006, Pages

  Smalling, Richard W ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ALTEPLASE; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ENOXAPARIN; FIBRINOLYTIC AGENT; HEPARIN; LANOTEPLASE; RETEPLASE; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CLINICAL TRIAL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; META ANALYSIS; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REPERFUSION; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; EMERGENCY HEALTH SERVICE; REVIEW;

EMERGENCY MEDICAL SERVICES; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY;

EID: 33745169348     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2006.04.009     Document Type: Article

References (35)

1. Braunwald E. The open-artery theory is alive and well-again. N Engl J Med 329 (1993) 1650-1652
2. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329 (1993) 673-682
3. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med 329 (1993) 1615-1622
4. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110 (2004) e82-e292
5. Bassand J.P., Danchin N., Filippatos G., et al. Implementation of reperfusion therapy in acute myocardial infarction. A policy statement from the European Society of Cardiology. Eur Heart J 26 (2005) 2733-2741
6. Keeley E.C., Boura J.A., and Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 361 (2003) 13-20
7. Waters R.E., Singh K.P., Roe M.T., et al. Rationale and strategies for implementing community-based transfer protocols for primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. J Am Coll Cardiol 43 (2004) 2153-2159
8. Nallamothu B.K., Bates E.R., Herrin J., et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 111 (2005) 761-767
9. Collen D., and Lijnen H.R. Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost 2 (2004) 541-546
10. Chesebro J.H., Knatterud G., Roberts R., et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76 (1987) 142-154
11. Llevadot J., Giugliano R.P., and Antman E.M. Bolus fibrinolytic therapy in acute myocardial infarction. JAMA 286 (2001) 442-449
12. The InTIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early; InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 21 (2000) 2005-2013
13. Smalling R.W., Bode C., Kalbfleisch J., et al. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators. Circulation 91 (1995) 2725-3732
14. Bode C., Smalling R.W., Berg G., et al. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators. Circulation 94 (1996) 891-898
15. Smalling R.W., and Giesler G. The level I cardiovascular center: is it time?. Am Heart Hosp J 1 (2003) 170-174
16. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics. Lancet 346 (1995) 329-336
17. The Gusto III Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med 337 (1997) 1118-1123
18. The ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic Investigators. Lancet 354 (1999) 716-722
19. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358 (2001) 605-613
20. Sinnaeve P.R., Alexander J.H., Bogaerts K., et al. Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction. Am Heart J 147 (2004) 993-998
21. Topol E.J. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 357 (2001) 1905-1914
22. Cannon C.P., Gibson C.M., McCabe C.H., et al. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial. Thrombolysis in Myocardial Infarction (TIMI) 10B Investigators. Circulation 98 (1998) 2805-2814
23. O'Connor G.T., Quinton H.B., Traven N.D., et al. Geographic variation in the treatment of acute myocardial infarction: the Cooperative Cardiovascular Project. JAMA 281 (1999) 627-633
24. Zahn R., Schiele R., Schneider S., et al. Primary angioplasty versus intravenous thrombolysis in acute myocardial infarction: can we define subgroups of patients benefiting most from primary angioplasty? Results from the pooled data of the Maximal Individual Therapy in Acute Myocardial Infarction Registry and the Myocardial Infarction Registry. J Am Coll Cardiol 37 (2001) 1827-1835
25. De Luca G., Suryapranata H., Ottervanger J.T., et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation 109 (2004) 1223-1225
26. Boersma E., Maas A.C., Deckers J.W., et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 348 (1996) 771-775
27. Stone G.W., Cox D., Garcia E., et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation 104 (2001) 636-641
28. Thiele H., Engelmann L., Elsner K., et al. Comparison of pre-hospital combination-fibrinolysis plus conventional care with pre-hospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 26 (2005) 1956-1963
29. Morrow D.A., Antman E.M., Sayah A., et al. Evaluation of the time saved by prehospital initiation of reteplase for ST-elevation myocardial infarction: results of The Early RetavaseThrombolysis in Myocardial Infarction (ERTIMI) 19 trial. J Am Coll Cardiol 40 (2002) 71-77
30. Wallentin L., Goldstein P., Armstrong P.W., et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 108 (2003) 135-142
31. Danchin N., Blanchard D., Steg P.G., et al. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation 110 (2004) 1909-1915
32. Bonnefoy E., Lapostolle F., Leizorovicz A., et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 360 (2002) 825-829
33. Steg P.G., Bonnefoy E., Chabaud S., et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 108 (2003) 2851-2856
34. Morrison L.J., Verbeek P.R., McDonald A.C., et al. Mortality and prehospital thrombolysis for acute myocardial infarction: A meta-analysis. JAMA 283 (2000) 2686-2692
35. Giesler G.M., Vooletich M., Julapalli V., et al. Coordinated aggressive medical and interventional therapy for acute myocardial infarction: pre-hospital administration of thrombolysis with urgent culprit artery revascularization (PATCAR). Am J Cardiol 96 Suppl 1 (2005) 56H